Fennec Pharmaceuticals Inc. (FENC)
USD 6.3
(3.11%)
USD 6.3
(3.11%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -12.77 Million USD | 42.43% |
| 2022 | -22.58 Million USD | -31.16% |
| 2021 | -17.22 Million USD | 3.7% |
| 2020 | -17.88 Million USD | -37.48% |
| 2019 | -13 Million USD | -24.98% |
| 2018 | -10.4 Million USD | -49.75% |
| 2017 | -6.95 Million USD | -142.11% |
| 2016 | -2.87 Million USD | -51.9% |
| 2015 | -1.89 Million USD | 34.31% |
| 2014 | -2.87 Million USD | -48.99% |
| 2013 | -1.93 Million USD | 46.66% |
| 2012 | -3.62 Million USD | -5.29% |
| 2011 | -3.43 Million USD | 25.33% |
| 2010 | -4.6 Million USD | -43.16% |
| 2009 | -3.21 Million USD | 76.84% |
| 2008 | -13.88 Million USD | 2.14% |
| 2007 | -14.19 Million USD | 25.56% |
| 2006 | -19.06 Million USD | -3.91% |
| 2005 | -18.34 Million USD | -94.72% |
| 2004 | -9.42 Million USD | -39.69% |
| 2003 | -6.74 Million USD | -66.91% |
| 2002 | -4.04 Million USD | -52.56% |
| 2001 | -2.64 Million USD | -64.97% |
| 2000 | -1.6 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5.03 Million USD | -136.82% |
| 2024 Q1 | 13.68 Million USD | 832.32% |
| 2023 Q2 | -4.66 Million USD | 12.65% |
| 2023 FY | -13 Million USD | 42.43% |
| 2023 Q3 | -1.01 Million USD | 78.2% |
| 2023 Q4 | -1.86 Million USD | -83.7% |
| 2023 Q1 | -5.34 Million USD | 12.93% |
| 2022 FY | -22.58 Million USD | -31.16% |
| 2022 Q1 | -3.54 Million USD | 15.71% |
| 2022 Q4 | -6.13 Million USD | 22.33% |
| 2022 Q3 | -7.89 Million USD | -57.7% |
| 2022 Q2 | -5 Million USD | -41.26% |
| 2021 Q3 | -4.17 Million USD | -6.45% |
| 2021 FY | -17.22 Million USD | 3.7% |
| 2021 Q1 | -4.92 Million USD | -47.13% |
| 2021 Q2 | -3.92 Million USD | 20.37% |
| 2021 Q4 | -4.2 Million USD | -0.81% |
| 2020 Q4 | -3.34 Million USD | 42.89% |
| 2020 Q1 | -3.83 Million USD | -4.98% |
| 2020 Q2 | -4.84 Million USD | -26.34% |
| 2020 Q3 | -5.85 Million USD | -20.93% |
| 2020 FY | -17.88 Million USD | -37.48% |
| 2019 FY | -13 Million USD | -24.98% |
| 2019 Q1 | -2.68 Million USD | 13.69% |
| 2019 Q2 | -4.81 Million USD | -79.59% |
| 2019 Q3 | -1.86 Million USD | 61.29% |
| 2019 Q4 | -3.65 Million USD | -96.08% |
| 2018 Q4 | -3.1 Million USD | -9.02% |
| 2018 Q2 | -2.66 Million USD | -48.8% |
| 2018 Q3 | -2.84 Million USD | -6.87% |
| 2018 FY | -10.4 Million USD | -49.75% |
| 2018 Q1 | -1.79 Million USD | 28.79% |
| 2017 Q3 | -2.18 Million USD | -47.8% |
| 2017 Q4 | -2.51 Million USD | -15.05% |
| 2017 FY | -6.95 Million USD | -142.11% |
| 2017 Q1 | -771 Thousand USD | 32.72% |
| 2017 Q2 | -1.47 Million USD | -91.83% |
| 2016 Q2 | -707 Thousand USD | -55.73% |
| 2016 Q3 | -564 Thousand USD | 20.23% |
| 2016 FY | -2.87 Million USD | -51.9% |
| 2016 Q1 | -454 Thousand USD | 17.6% |
| 2016 Q4 | -1.14 Million USD | -103.19% |
| 2015 FY | -1.89 Million USD | 34.31% |
| 2015 Q4 | -551 Thousand USD | -63.02% |
| 2015 Q3 | -338 Thousand USD | 38.43% |
| 2015 Q2 | -549 Thousand USD | -21.46% |
| 2015 Q1 | -452 Thousand USD | 42.86% |
| 2014 Q2 | -930 Thousand USD | -73.18% |
| 2014 Q4 | -791 Thousand USD | -27.79% |
| 2014 Q3 | -619 Thousand USD | 33.44% |
| 2014 FY | -2.87 Million USD | -48.99% |
| 2014 Q1 | -537 Thousand USD | -29.09% |
| 2013 Q1 | -537 Thousand USD | 52.18% |
| 2013 Q2 | -927 Thousand USD | -72.63% |
| 2013 Q3 | -51 Thousand USD | 94.5% |
| 2013 Q4 | -416 Thousand USD | -715.69% |
| 2013 FY | -1.93 Million USD | 46.66% |
| 2012 Q2 | -1.25 Million USD | -102.92% |
| 2012 Q3 | -630 Thousand USD | 49.6% |
| 2012 Q4 | -1.12 Million USD | -78.25% |
| 2012 FY | -3.62 Million USD | -5.29% |
| 2012 Q1 | -616 Thousand USD | 31.71% |
| 2011 Q1 | -1.02 Million USD | -25.12% |
| 2011 FY | -3.43 Million USD | 25.33% |
| 2011 Q4 | -902 Thousand USD | 4.45% |
| 2011 Q3 | -944 Thousand USD | -65.03% |
| 2011 Q2 | -572 Thousand USD | 43.98% |
| 2010 Q2 | -442.00 USD | 99.88% |
| 2010 Q1 | -366 Thousand USD | -1089.19% |
| 2010 FY | -4.6 Million USD | -43.16% |
| 2010 Q3 | -917 Thousand USD | -207366.06% |
| 2010 Q4 | -816 Thousand USD | 11.01% |
| 2009 Q1 | -1.95 Million USD | 26.06% |
| 2009 Q2 | -961 Thousand USD | 50.77% |
| 2009 Q4 | 37 Thousand USD | 110.88% |
| 2009 Q3 | -340 Thousand USD | 64.62% |
| 2009 FY | -3.21 Million USD | 76.84% |
| 2008 Q4 | -2.64 Million USD | 19.98% |
| 2008 Q3 | -3.29 Million USD | 6.04% |
| 2008 Q2 | -3.51 Million USD | 20.85% |
| 2008 Q1 | -4.43 Million USD | -39.5% |
| 2008 FY | -13.88 Million USD | 2.14% |
| 2007 Q2 | -3.43 Million USD | 16.43% |
| 2007 Q3 | -3.45 Million USD | -0.49% |
| 2007 FY | -14.19 Million USD | 25.56% |
| 2007 Q4 | -3.18 Million USD | 7.99% |
| 2007 Q1 | -4.11 Million USD | 23.46% |
| 2006 FY | -19.06 Million USD | -3.91% |
| 2006 Q3 | -5.31 Million USD | -17.47% |
| 2006 Q4 | -5.37 Million USD | -1.19% |
| 2006 Q2 | -4.52 Million USD | -17.45% |
| 2006 Q1 | -3.85 Million USD | 25.78% |
| 2005 Q3 | -4.8 Million USD | 2.82% |
| 2005 Q1 | -3.41 Million USD | -138.96% |
| 2005 Q4 | -5.18 Million USD | -8.08% |
| 2005 FY | -18.34 Million USD | -94.72% |
| 2005 Q2 | -4.94 Million USD | -44.58% |
| 2004 Q4 | 8.77 Million USD | 377.74% |
| 2004 Q2 | -2.9 Million USD | -7.27% |
| 2004 FY | -9.42 Million USD | -39.69% |
| 2004 Q1 | -2.7 Million USD | -25.35% |
| 2004 Q3 | -3.15 Million USD | -8.71% |
| 2003 Q1 | -1.89 Million USD | -61.39% |
| 2003 Q4 | -2.16 Million USD | -31.92% |
| 2003 Q3 | -1.63 Million USD | 30.21% |
| 2003 Q2 | -2.34 Million USD | -23.52% |
| 2003 FY | -6.74 Million USD | -66.91% |
| 2002 Q3 | -1.14 Million USD | 23.24% |
| 2002 Q4 | -1.17 Million USD | -2.75% |
| 2002 Q2 | -1.49 Million USD | -64.08% |
| 2002 Q1 | -909.61 Thousand USD | -30.83% |
| 2002 FY | -4.04 Million USD | -52.56% |
| 2001 Q4 | -695.25 Thousand USD | 27.07% |
| 2001 Q3 | -953.32 Thousand USD | 64.01% |
| 2001 Q2 | -2.64 Million USD | -417585523.13% |
| 2001 Q1 | 0.63 USD | 100.0% |
| 2001 FY | -2.64 Million USD | -64.97% |
| 2000 FY | -1.6 Million USD | 0.0% |
| 2000 Q4 | -558.82 Thousand USD | -83985942.68% |
| 2000 Q3 | 0.67 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Sangamo Therapeutics, Inc. | -274 Million USD | 95.339% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 90.5% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -971.393% |
| Autolus Therapeutics plc | -195.02 Million USD | 93.452% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -36.912% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 56.554% |
| Shattuck Labs, Inc. | -91.95 Million USD | 86.112% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 82.532% |
| CervoMed Inc. | -7.81 Million USD | -63.461% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 95.082% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 71.669% |
| Aptose Biosciences Inc. | -52.35 Million USD | 75.607% |
| Precision BioSciences, Inc. | -43.73 Million USD | 70.8% |
| Dyadic International, Inc. | -8.22 Million USD | -55.181% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 86.335% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | -53.516% |
| Nektar Therapeutics | -137.42 Million USD | 90.707% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -96.962% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 56.35% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 82.663% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 85.328% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 94.375% |
| GRI Bio, Inc. | -11.38 Million USD | -12.154% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -182.812% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 90.265% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | -5.992% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -364.092% |
| IGM Biosciences, Inc. | -263.46 Million USD | 95.153% |
| INmune Bio, Inc. | -29.74 Million USD | 57.059% |
| Opthea Limited | -191.84 Million USD | 93.343% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 79.098% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 87.262% |
| Verastem, Inc. | -92.08 Million USD | 86.131% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 72.905% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 93.065% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 89.212% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 206.942% |
| NextCure, Inc. | -67.63 Million USD | 81.118% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 36.43% |
| Organovo Holdings, Inc. | -15.08 Million USD | 15.345% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -150.892% |
| Arvinas, Inc. | -401.5 Million USD | 96.819% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 78.457% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 49.482% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 80.679% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 92.544% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 83.67% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 90.099% |
| Senti Biosciences, Inc. | -92.72 Million USD | 86.227% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 16.095% |
| Apollomics, Inc. | -54.83 Million USD | 76.71% |
| PureTech Health plc | -146.19 Million USD | 91.265% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 69.384% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 84.781% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 92.285% |
| Synaptogenix, Inc. | -8.31 Million USD | -53.611% |
| ChromaDex Corporation | -5.59 Million USD | -128.094% |
| Beam Therapeutics Inc. | -176.48 Million USD | 92.764% |
| Monopar Therapeutics Inc. | -8.83 Million USD | -44.612% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 72.391% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 91.764% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 97.53% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | -58.806% |
| Gritstone bio, Inc. | -154.63 Million USD | 91.741% |
| Mesoblast Limited | -58.79 Million USD | 78.278% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 18.603% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 70.982% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 93.296% |
| MediWound Ltd. | -15.29 Million USD | 16.475% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 92.566% |
| Fortress Biotech, Inc. | -142.34 Million USD | 91.028% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 74.878% |
| Achilles Therapeutics plc | -75.25 Million USD | 83.03% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 88.173% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 75.51% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 59.298% |
| Zai Lab Limited | -366.57 Million USD | 96.516% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -100.802% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 94.798% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 8.465% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 91.079% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 95.468% |
| Celcuity Inc. | -66.23 Million USD | 80.717% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 10.127% |
| ContextLogic Inc. | -328 Million USD | 96.106% |
| GH Research PLC | -41.22 Million USD | 69.019% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 86.928% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 49.825% |
| ImmuCell Corporation | -5.74 Million USD | -122.179% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 132.913% |
| Amarin Corporation plc | -67.58 Million USD | 81.105% |
| TG Therapeutics, Inc. | 20.63 Million USD | 161.896% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 55.776% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 81.454% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 88.165% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 50.253% |
| Aptorum Group Limited | -10.52 Million USD | -21.359% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 97.756% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 87.686% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 49.837% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 93.77% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 34.233% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 89.949% |
| Ardelyx, Inc. | -63.27 Million USD | 79.817% |
| Ainos, Inc. | -13.2 Million USD | 3.297% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 80.973% |
| Prothena Corporation plc | -191.03 Million USD | 93.315% |
| HilleVax, Inc. | -133.34 Million USD | 90.423% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 90.748% |
| Celularity Inc. | -192.28 Million USD | 93.358% |
| Rallybio Corporation | -78.93 Million USD | 83.82% |
| Cue Biopharma, Inc. | -52.14 Million USD | 75.511% |
| Omeros Corporation | -164.53 Million USD | 92.238% |
| Humacyte, Inc. | -100.04 Million USD | 87.235% |
| Immunocore Holdings plc | -59.64 Million USD | 78.59% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 31.187% |
| Blueprint Medicines Corporation | -486.27 Million USD | 97.374% |
| IO Biotech, Inc. | -91.44 Million USD | 86.034% |
| MEI Pharma, Inc. | 14.54 Million USD | 187.821% |
| GT Biopharma, Inc. | -13.57 Million USD | 5.93% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 82.894% |
| Summit Therapeutics Inc. | -89.73 Million USD | 85.768% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 62.731% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 90.287% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 92.544% |
| Pulmatrix, Inc. | -14.74 Million USD | 13.358% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 64.272% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 88.122% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 85.629% |
| Acelyrin, Inc. | -422.06 Million USD | 96.974% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 97.522% |
| Cytokinetics, Incorporated | -496.2 Million USD | 97.426% |
| Vor Biopharma Inc. | -126.03 Million USD | 89.867% |
| Evogene Ltd. | -26.39 Million USD | 51.609% |
| Replimune Group, Inc. | -234.77 Million USD | 94.56% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 80.211% |
| PDS Biotechnology Corporation | -43.04 Million USD | 70.331% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | -66.024% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 97.897% |
| AEON Biopharma, Inc. | -48.42 Million USD | 73.629% |
| BioLineRx Ltd. | -49.69 Million USD | 74.301% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 66.456% |
| Atai Life Sciences N.V. | -125.47 Million USD | 89.822% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 84.313% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 61.325% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 94.871% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 58.455% |
| MediciNova, Inc. | -9.9 Million USD | -28.997% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 89.894% |
| MiMedx Group, Inc. | 37.11 Million USD | 134.408% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -76.335% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 94.491% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 96.345% |
| Mereo BioPharma Group plc | -28.41 Million USD | 55.057% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 94.446% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 53.706% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 94.726% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -166.536% |
| Allakos Inc. | -196.05 Million USD | 93.486% |
| scPharmaceuticals Inc. | -55.39 Million USD | 76.946% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 88.46% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 111.904% |
| NLS Pharmaceutics AG | -11.8 Million USD | -8.164% |
| Precigen, Inc. | -88.92 Million USD | 85.638% |
| XOMA Corporation | -41.84 Million USD | 69.482% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 87.865% |
| Incyte Corporation | 620.52 Million USD | 102.058% |
| Alzamend Neuro, Inc. | -9.93 Million USD | -28.511% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 89.488% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 85.392% |
| Seer, Inc. | -103.46 Million USD | 87.656% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 47.459% |
| CRISPR Therapeutics AG | -222.53 Million USD | 94.261% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 92.612% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 40.506% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | -55.502% |
| Akari Therapeutics, Plc | -16.8 Million USD | 24.009% |
| Novavax, Inc. | -566.51 Million USD | 97.746% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -95.454% |
| UroGen Pharma Ltd. | -65.53 Million USD | 80.513% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 85.695% |
| Entera Bio Ltd. | -8.89 Million USD | -43.64% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 50.323% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 88.873% |
| Chimerix, Inc. | -93.06 Million USD | 86.277% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 84.623% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 92.367% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 75.961% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 102.207% |
| AnaptysBio, Inc. | -164.41 Million USD | 92.232% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 17.457% |
| Portage Biotech Inc. | -18.25 Million USD | 30.033% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 87.833% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 84.063% |
| OKYO Pharma Limited | -15.74 Thousand USD | -80987.104% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -12.969% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | -67.316% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -11.468% |
| AbCellera Biologics Inc. | -237.2 Million USD | 94.616% |
| Genprex, Inc. | -31.07 Million USD | 58.903% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 93.214% |
| NLS Pharmaceutics AG | -11.8 Million USD | -8.164% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -134.463% |
| Daré Bioscience, Inc. | -30.83 Million USD | 58.589% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -75.498% |
| Bicycle Therapeutics plc | -189.94 Million USD | 93.277% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 97.379% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 86.363% |
| Erasca, Inc. | -141.52 Million USD | 90.976% |
| bluebird bio, Inc. | -244.26 Million USD | 94.772% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 57.081% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 106.568% |
| DBV Technologies S.A. | -76.43 Million USD | 83.291% |
| Fortress Biotech, Inc. | -142.34 Million USD | 91.028% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 94.579% |
| CorMedix Inc. | -48.95 Million USD | 73.914% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 96.61% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 65.543% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 75.205% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 75.437% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 91.736% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 85.221% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 93.864% |
| Onconetix, Inc. | -36.03 Million USD | 64.559% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | -20.903% |
| Prime Medicine, Inc. | -191.29 Million USD | 93.324% |
| Adagene Inc. | -23.71 Million USD | 46.159% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 94.174% |
| GlycoMimetics, Inc. | -39.27 Million USD | 67.483% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 59.647% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 94.276% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 110.467% |
| SciSparc Ltd. | -5.77 Million USD | -121.219% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -47.528% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 44.761% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 84.619% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 159.453% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -144318.825% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 94.703% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 12.416% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 95.474% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -24.147% |
| 2seventy bio, Inc. | -216.7 Million USD | 94.107% |
| ADMA Biologics, Inc. | 21.63 Million USD | 159.038% |
| Clene Inc. | -40.54 Million USD | 68.498% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 46.96% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 76.694% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 96.352% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 65.232% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 179.436% |
| Absci Corporation | -115.51 Million USD | 88.944% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 100.316% |
| Surrozen, Inc. | -45.78 Million USD | 72.104% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 88.996% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 82.5% |
| Cingulate Inc. | -22.75 Million USD | 43.886% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 270.462% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | -55.102% |
| Jaguar Health, Inc. | -34.29 Million USD | 62.757% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 87.548% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 82.596% |
| Kronos Bio, Inc. | -121.83 Million USD | 89.517% |
| Innoviva, Inc. | 176.7 Million USD | 107.227% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 83.239% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -303.89% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 11.44% |
| Soligenix, Inc. | -7.69 Million USD | -65.902% |
| AlloVir, Inc. | -181.33 Million USD | 92.957% |
| Century Therapeutics, Inc. | -146.54 Million USD | 91.285% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 88.472% |
| Kura Oncology, Inc. | -165.8 Million USD | 92.298% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -414.62% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 84.914% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 39.574% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 66.276% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 88.455% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 66.459% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 20.078% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 19.021% |
| HCW Biologics Inc. | -25.71 Million USD | 50.341% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 90.814% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 95.373% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 93.715% |
| Lantern Pharma Inc. | -17.87 Million USD | 28.564% |
| Histogen Inc. | -10.64 Million USD | -19.994% |
| Surrozen, Inc. | -45.78 Million USD | 72.104% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 70.3% |
| Kodiak Sciences Inc. | -277.32 Million USD | 95.395% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 76.404% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 73.64% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 89.683% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 45.526% |
| Moderna, Inc. | -4.23 Billion USD | 99.699% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 96.39% |
| Turnstone Biologics Corp. | -59.03 Million USD | 78.366% |
| Immix Biopharma, Inc. | -16.14 Million USD | 20.879% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 12.443% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 86.072% |
| Exelixis, Inc. | 170.88 Million USD | 107.473% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 91.089% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 81.218% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -129.612% |
| Alkermes plc | 414.12 Million USD | 103.084% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 81.454% |
| Arcellx, Inc. | -89.88 Million USD | 85.791% |
| ESSA Pharma Inc. | -32.13 Million USD | 60.257% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 25.416% |
| Avid Bioservices, Inc. | -18.67 Million USD | 31.625% |
| Insmed Incorporated | -709.62 Million USD | 98.2% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 71.877% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 90.692% |
| Moolec Science SA | -6.65 Million USD | -91.935% |
| RenovoRx, Inc. | -11.39 Million USD | -12.066% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 79.111% |
| Geron Corporation | -193.94 Million USD | 93.415% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 70.474% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 80.579% |
| Royalty Pharma plc | 1.49 Billion USD | 100.856% |
| OmniAb, Inc. | -69.41 Million USD | 81.603% |
| Alector, Inc. | -151.74 Million USD | 91.584% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 92.22% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 92.53% |
| Humacyte, Inc. | -100.04 Million USD | 87.235% |
| Structure Therapeutics Inc. | -102.77 Million USD | 87.574% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 95.968% |
| 89bio, Inc. | -151.2 Million USD | 91.554% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 12.166% |
| Aura Biosciences, Inc. | -84.99 Million USD | 84.974% |
| Immunic, Inc. | -99.22 Million USD | 87.129% |
| Veracyte, Inc. | -85.79 Million USD | 85.115% |
| Genelux Corporation | -24.16 Million USD | 47.151% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 62.353% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -85.411% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 32.042% |
| Immunovant, Inc. | -282.7 Million USD | 95.483% |
| Vericel Corporation | -6.46 Million USD | -97.571% |
| Fortrea Holdings Inc. | 63.1 Million USD | 120.239% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 90.907% |
| XBiotech Inc. | -37.51 Million USD | 65.953% |
| Agenus Inc. | -159.54 Million USD | 91.996% |
| Acasti Pharma Inc. | -11.31 Million USD | -12.898% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | -1.463% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 44.283% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 20.078% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 76.036% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 83.73% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 19.608% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 42.61% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 56.199% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 56.42% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 93.073% |
| United Therapeutics Corporation | 1.18 Billion USD | 101.078% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -127.237% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 61.074% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -150.892% |
| Silo Pharma, Inc. | -3.85 Million USD | -231.233% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -223.969% |
| Pharming Group N.V. | -4.87 Million USD | -161.725% |
| XOMA Corporation | -41.84 Million USD | 69.482% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 47.459% |
| Bionomics Limited | -17.89 Billion USD | 99.929% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 135.793% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 84.463% |
| uniQure N.V. | -282.87 Million USD | 95.485% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 83.861% |
| Cassava Sciences, Inc. | -105.95 Million USD | 87.947% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -147.76% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 27.185% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 90.139% |
| Pluri Inc. | -22.15 Million USD | 42.364% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | -53.705% |
| MeiraGTx Holdings plc | -137.06 Million USD | 90.682% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 47.837% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 32.42% |
| CalciMedica, Inc. | -21.87 Million USD | 41.618% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 96.093% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 82.623% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -98938.848% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 135.793% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 81.094% |
| Nutriband Inc. | -4.87 Million USD | -162.135% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 70.717% |
| Compugen Ltd. | -12.99 Million USD | 1.701% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 100.301% |
| ProKidney Corp. | -151.52 Million USD | 91.572% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -182.109% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -248.072% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 88.814% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 84.357% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 74.254% |
| Benitec Biopharma Inc. | -22.49 Million USD | 43.215% |
| GeoVax Labs, Inc. | -26.74 Million USD | 52.245% |
| Biomea Fusion, Inc. | -126.13 Million USD | 89.875% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 93.317% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 88.685% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 49.313% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 44.224% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 94.729% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 93.86% |
| Imunon, Inc. | -21.03 Million USD | 39.274% |
| BioAtla, Inc. | -129.68 Million USD | 90.152% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 96.103% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 69.417% |
| Zura Bio Limited | -62.63 Million USD | 79.611% |
| aTyr Pharma, Inc. | -54.91 Million USD | 76.746% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 96.644% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 94.981% |
| Galecto, Inc. | -39.9 Million USD | 67.996% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -144318.825% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 103.783% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 92.564% |
| PolyPid Ltd. | -22.86 Million USD | 44.151% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 21.535% |
| Forte Biosciences, Inc. | -32.48 Million USD | 60.688% |
| Xencor, Inc. | -138.63 Million USD | 90.788% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 40.575% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -95.454% |
| Instil Bio, Inc. | -159.16 Million USD | 91.976% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -76.335% |
| OncoCyte Corporation | -25.13 Million USD | 49.192% |
| Elevation Oncology, Inc. | -45.44 Million USD | 71.898% |
| Purple Biotech Ltd. | 22.27 Million USD | 157.344% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | -70.008% |
| MacroGenics, Inc. | -168.24 Million USD | 92.409% |
| Verona Pharma plc | -67.83 Million USD | 81.172% |
| Tharimmune, Inc. | -9.45 Million USD | -35.068% |
| Apogee Therapeutics, Inc. | -93 Million USD | 86.268% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 50.994% |
| Aditxt, Inc. | -26.06 Million USD | 50.998% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -1569.412% |
| Savara Inc. | -60 Million USD | 78.717% |
| Curis, Inc. | -48.33 Million USD | 73.577% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -144.783% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 53.134% |
| BeiGene, Ltd. | -1.2 Billion USD | 98.943% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -182.109% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 70.027% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 4.129% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 81.006% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 37.675% |
| Adicet Bio, Inc. | -152.03 Million USD | 91.6% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -74.704% |
| Quantum-Si incorporated | -111.17 Million USD | 88.512% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 12.394% |
| Generation Bio Co. | -138.56 Million USD | 90.783% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 85.229% |
| Invivyd, Inc. | -207.78 Million USD | 93.854% |
| Relay Therapeutics, Inc. | -373 Million USD | 96.576% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | -36.173% |
| Moolec Science SA | -6.65 Million USD | -91.935% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 48.595% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 77.5% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 87.685% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 92.5% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 98.134% |
| Evaxion Biotech A/S | -22.19 Million USD | 42.465% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 84.498% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 84.025% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 71.408% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 79.426% |
| Clearmind Medicine Inc. | -8.74 Million USD | -46.099% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 82.246% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 114.711% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -335.427% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 87.334% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 92.485% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 94.263% |
| ImmunityBio, Inc. | -362.25 Million USD | 96.475% |
| Korro Bio, Inc. | -84.53 Million USD | 84.892% |
| Kineta, Inc. | -15.72 Million USD | 18.775% |
| BioVie Inc. | -32.17 Million USD | 60.313% |
| Codexis, Inc. | -68.06 Million USD | 81.238% |
| Celularity Inc. | -192.28 Million USD | 93.358% |
| Virax Biolabs Group Limited | -6.49 Million USD | -96.584% |
| Cibus, Inc. | -318.88 Million USD | 95.995% |
| Annexon, Inc. | -143.72 Million USD | 91.114% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 80.245% |
| Eyenovia, Inc. | -25.4 Million USD | 49.733% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 139.127% |
| NeurAxis, Inc. | -6.66 Million USD | -91.627% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 58.948% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 74.642% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 41.671% |
| Notable Labs, Ltd. | -14.65 Million USD | 12.868% |
| IN8bio, Inc. | -30.33 Million USD | 57.903% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 39.949% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 87.481% |
| Lumos Pharma, Inc. | -36.61 Million USD | 65.12% |
| Liquidia Corporation | -73.38 Million USD | 82.597% |
| Mustang Bio, Inc. | -50.72 Million USD | 74.824% |
| Quantum-Si incorporated | -111.17 Million USD | 88.512% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 83.649% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 50.994% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 81.086% |
| 180 Life Sciences Corp. | -13.47 Million USD | 5.242% |
| Vaxcyte, Inc. | -468.04 Million USD | 97.271% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 94.034% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -74.704% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 57.066% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 347.677% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -335.427% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 69.14% |
| PepGen Inc. | -84.76 Million USD | 84.934% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 56.9% |
| Solid Biosciences Inc. | -104.31 Million USD | 87.757% |
| Palisade Bio, Inc. | -13.07 Million USD | 2.288% |
| Nutriband Inc. | -4.87 Million USD | -162.135% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -129.612% |
| Immuneering Corporation | -58.41 Million USD | 78.137% |
| Belite Bio, Inc | -31.66 Million USD | 59.672% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 76.968% |
| GeoVax Labs, Inc. | -26.74 Million USD | 52.245% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 71.876% |
| Altimmune, Inc. | -95.92 Million USD | 86.687% |
| Peak Bio, Inc. | -1356.23 USD | -941554.439% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 10.127% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | -43.672% |
| Neurogene Inc. | -55.58 Million USD | 77.024% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 88.3% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -50.229% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 86.795% |
| Sesen Bio, Inc. | -25.9 Million USD | 50.708% |
| argenx SE | -425.04 Million USD | 96.995% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 57.066% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 73.49% |
| Immunome, Inc. | -109.53 Million USD | 88.34% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 22.357% |
| Design Therapeutics, Inc. | -78.19 Million USD | 83.667% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 68.466% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 84.711% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 97.227% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 82.37% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 90.556% |
| Athira Pharma, Inc. | -125.46 Million USD | 89.821% |
| XOMA Corporation | -41.84 Million USD | 69.482% |
| Merus N.V. | -156.54 Million USD | 91.842% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 63.111% |
| Rezolute, Inc. | -70.42 Million USD | 81.865% |
| Clene Inc. | -40.54 Million USD | 68.498% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 22.026% |
| BeyondSpring Inc. | -23.11 Million USD | 44.748% |
| Synlogic, Inc. | -55.16 Million USD | 76.848% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 28.769% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -17.988% |
| Peak Bio, Inc. | -1356.23 USD | -941554.439% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 68.469% |
| Krystal Biotech, Inc. | -109.72 Million USD | 88.361% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 90.141% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 96.277% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -169.092% |
| MannKind Corporation | 8.67 Million USD | 247.165% |
| Ikena Oncology, Inc. | -75.41 Million USD | 83.066% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | -32.383% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 81.004% |
| Gossamer Bio, Inc. | -183.75 Million USD | 93.05% |
| CohBar, Inc. | -12.38 Million USD | -3.089% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 74.823% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 53.706% |
| Legend Biotech Corporation | -439.48 Million USD | 97.094% |
| Mural Oncology plc | -194.63 Million USD | 93.439% |
| Disc Medicine, Inc. | -91.12 Million USD | 85.985% |
| Champions Oncology, Inc. | -7.35 Million USD | -73.613% |
| REGENXBIO Inc. | -268.12 Million USD | 95.237% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -19.153% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 77.095% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 67.221% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 88.832% |
| Vaxart, Inc. | -83.34 Million USD | 84.677% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | -49.894% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 70.157% |
| Cellectis S.A. | -106.62 Million USD | 88.023% |
| Longeveron Inc. | -21.02 Million USD | 39.27% |
| Repare Therapeutics Inc. | -116.22 Million USD | 89.012% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 95.232% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 83.117% |
| Revolution Medicines, Inc. | -487.18 Million USD | 97.379% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -91.987% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 70.945% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 82.878% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 81.66% |
| Anixa Biosciences, Inc. | -11.01 Million USD | -15.984% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 100.296% |
| Denali Therapeutics Inc. | -196.69 Million USD | 93.507% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -47.528% |
| Veru Inc. | -93.78 Million USD | 86.382% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 45.257% |
| Cingulate Inc. | -22.75 Million USD | 43.886% |
| Passage Bio, Inc. | -108.38 Million USD | 88.217% |
| Context Therapeutics Inc. | -25.07 Million USD | 49.064% |
| Exicure, Inc. | -14.99 Million USD | 14.837% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 93.802% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 68.543% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | -31.43% |
| Nuvalent, Inc. | -149.49 Million USD | 91.457% |
| ABVC BioPharma, Inc. | -8.21 Million USD | -55.431% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 85.607% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 38.524% |
| OmniAb, Inc. | -69.41 Million USD | 81.603% |
| Anew Medical, Inc. | -1.3 Million USD | -881.75% |
| Lipocine Inc. | -17.93 Million USD | 28.777% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 81.36% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 83.23% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 66.459% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 67.69% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 42.946% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 97.798% |
| Ocugen, Inc. | -65.53 Million USD | 80.512% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 86.394% |
| Q32 Bio Inc. | -92.1 Million USD | 86.134% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 40.431% |
| Alumis Inc. Common Stock | -158.17 Million USD | 91.926% |
| Equillium, Inc. | -14.52 Million USD | 12.058% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 79.536% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -61.59% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 32.304% |
| Dominari Holdings Inc. | -21.79 Million USD | 41.407% |
| Edesa Biotech, Inc. | -9.22 Million USD | -38.473% |
| vTv Therapeutics Inc. | -25.5 Million USD | 49.922% |
| Bio-Techne Corporation | 206.68 Million USD | 106.179% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 96.738% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 106.651% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 90.345% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 66.734% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 91.548% |
| Nkarta, Inc. | -131.65 Million USD | 90.299% |
| BioCardia, Inc. | -11.64 Million USD | -9.679% |
| Iterum Therapeutics plc | -47.46 Million USD | 73.096% |